Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses
| العنوان: | Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses |
|---|---|
| المؤلفون: | Thomas Brodowicz, K Koynov, Rodica Anghel, Diethelm Messinger, Richard Greil, Zsuzsanna Kahán, Semir Beslija, Lubos Petruzelka, Salomon M. Stemmer, Christoph C. Zielinski, Tadeusz Pienkowski, S Ahlers, Alexandru Eniu, Damir Vrbanec, Bohuslav Melichar, István Láng, Stanislav Spanik, Moshe Inbar, Bella Kaufman |
| المصدر: | British Journal of Cancer |
| بيانات النشر: | Springer Science and Business Media LLC, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Adult, Oncology, bevacizumab, metastatic breast cancer, triple-negative breast cancer, risk factor, prognostic index, Cancer Research, medicine.medical_specialty, genetic structures, Bevacizumab, Receptor, ErbB-2, Advanced breast, First line, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Risk Factors, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Risk factor, skin and connective tissue diseases, Triple-negative breast cancer, Aged, Aged, 80 and over, business.industry, Cancer, Middle Aged, medicine.disease, Metastatic breast cancer, eye diseases, Clinical trial, Clinical Study, Female, sense organs, business, medicine.drug |
| الوصف: | Background: The randomised phase III TURANDOT trial compared first-line bevacizumab–paclitaxel (BEV–PAC) vs bevacizumab–capecitabine (BEV–CAP) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). The interim analysis revealed no difference in overall survival (OS; primary end point) between treatment arms; however, progression-free survival (PFS) and objective response rate were significantly superior with BEV–PAC. We sought to identify patient populations that may be most appropriately treated with one or other regimen. Methods: Patients with HER2-negative LR/mBC who had received no prior chemotherapy for advanced disease were randomised to either BEV–PAC (bevacizumab 10 mg kg−1 days 1 and 15 plus paclitaxel 90 mg m−2 days 1, 8 and 15 q4w) or BEV–CAP (bevacizumab 15 mg kg−1 day 1 plus capecitabine 1000 mg m−2 bid days 1–14 q3w). The study population was categorised into three cohorts: triple-negative breast cancer (TNBC), high-risk hormone receptor-positive (HR+) and low-risk HR+. High- and low-risk HR+ were defined, respectively, as having ⩾2 vs ⩽1 of the following four risk factors: disease-free interval ⩽24 months; visceral metastases; prior (neo)adjuvant anthracycline and/or taxane; and metastases in ⩾3 organs. Results: The treatment effect on OS differed between cohorts. Non-significant OS trends favoured BEV–PAC in the TNBC cohort and BEV–CAP in the low-risk HR+ cohort. In all three cohorts, there was a non-significant PFS trend favouring BEV–PAC. Grade ⩾3 adverse events were consistently less common with BEV–CAP. Conclusions: A simple risk factor index may help in selecting bevacizumab-containing regimens, balancing outcome, safety profile and patient preference. Final OS results are expected in 2015 (ClinicalTrials.gov NCT00600340). |
| تدمد: | 1532-1827 0007-0920 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fc9a4d8721e35e6065ff6c7db932570Test https://doi.org/10.1038/bjc.2014.504Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5fc9a4d8721e35e6065ff6c7db932570 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15321827 00070920 |
|---|